文献速递神经核医学

评估白蛋白置换血浆置换治疗轻中度阿尔茨海默病的随机对照研究神经影像分析:AMBAR研究额外结果

Neuroimaging analyses from a randomized, controlled study to evaluate plasma exchange with albumin replacement in mild-to-moderate Alzheimer's disease: additional results from the AMBAR study.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2022-07-22

AMBAR 2b/3期随机对照试验的神经影像分析,轻中度阿尔茨海默病患者随机分为三个白蛋白血浆置换组(含低剂量白蛋白及低/高剂量白蛋白交替静脉免疫球蛋白)和安慰剂假血浆置换组。MRI分析(n=198)显示高白蛋白+静脉免疫球蛋白组部分皮质下结构体积变化较少;18FDG-PET分析(n=213)显示该组代谢稳定性最好、代谢下降百分比最小。

要点

  • MRI显示高白蛋白+静脉免疫球蛋白组皮质下结构体积变化较少,3个结构p<0.05。
  • 18FDG-PET显示高白蛋白+静脉免疫球蛋白组代谢稳定性最好,代谢下降百分比最小。
  • 白蛋白置换血浆置换与皮质下结构有害变化较少和代谢下降较少相关。

核心结论

  • 白蛋白置换血浆置换与皮质下结构有害变化较少及代谢下降较少相关,该效应在高白蛋白+静脉免疫球蛋白组更明显。

研究设计与样本

  • AMBAR 2b/3期随机对照试验的神经影像分析,轻中度阿尔茨海默病患者随机分为四组:三个接受白蛋白血浆置换组(一组低剂量白蛋白,两组低/高剂量白蛋白交替静脉免疫球蛋白)和安慰剂假血浆置换组。
  • 所有组接受6周每周常规血浆置换,随后12个月每月低容量血浆置换,进行MRI体积分析和18FDG-PET区域及统计参数映射分析。

主要发现

  • MRI分析(n=198)显示高白蛋白+静脉免疫球蛋白组从基线至末次访视体积变化较少,3个结构p<0.05,其他组为4至9个。
  • 高白蛋白+静脉免疫球蛋白组显示右侧海马无统计学显著缩小。
  • 18FDG-PET分析(n=213)显示阿尔茨海默病受累特定区域(后扣带回、楔前叶和顶颞区)代谢活性恶化。
  • 高白蛋白+静脉免疫球蛋白组在研究期间代谢稳定性最好,即代谢下降百分比最小(MaskAD),且与安慰剂相比缺陷进展最少。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study was designed to detect structural and functional brain changes in Alzheimer's disease (AD) patients treated with therapeutic plasma exchange (PE) with albumin replacement, as part of the recent AMBAR phase 2b/3 clinical trial. METHODS: Mild-to-moderate AD patients were randomized into four arms: three arms receiving PE with albumin (one with low-dose albumin, and two with low/high doses of albumin alternated with IVIG), and a placebo (sham PE) arm. All arms underwent 6 weeks of weekly conventional PE followed by 12 months of monthly low-volume PE. Magnetic resonance imaging (MRI) volumetric analyses and regional and statistical parametric mapping (SPM) analysis on 18F-fluorodeoxyglucose positron emission tomography (18FDG-PET) were performed. RESULTS: MRI analyses (n = 198 patients) of selected subcortical structures showed fewer volume changes from baseline to final visit in the high albumin + IVIG treatment group (p < 0.05 in 3 structures vs. 4 to 9 in other groups). The high albumin + IVIG group showed no statistically significant reduction of right hippocampus. SPM 18FDG-PET analyses (n = 213 patients) showed a worsening of metabolic activity in the specific areas affected in AD (posterior cingulate, precuneus, and parieto-temporal regions). The high-albumin + IVIG treatment group showed the greatest metabolic stability over the course of the study, i.e., the smallest percent decline in metabolism (MaskAD), and least progression of defect compared to placebo. CONCLUSIONS: PE with albumin replacement was associated with fewer deleterious changes in subcortical structures and less metabolic decline compared to the typical of the progression of AD. This effect was more marked in the group treated with high albumin + IVIG. TRIAL REGISTRATION: (AMBAR trial registration: EudraCT#: 2011-001,598-25; ClinicalTrials.gov ID: NCT01561053).

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Cuberas-Borrós G, Roca I, Castell-Conesa J, et al. Neuroimaging analyses from a randomized, controlled study to evaluate plasma exchange with albumin replacement in mild-to-moderate Alzheimer's disease: additional results from the AMBAR study. Eur J Nucl Med Mol Imaging. 2022. PMID: 35867135. doi:10.1007/s00259-022-05915-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。